Zydus Lifesciences — 360° view

Zydus Lifesciences, a company in the Pharmaceuticals industry, reported revenue of ₹7,910 crore and net profit of ₹928 crore for the September 2026 quarter.

Zydus Lifesciences (NSE: ZYDUSLIFE) closed at ₹1,200.00 on 20 Nov 2026, up 29.3% over the past year. Its market capitalisation is ₹1,19,700 crore and it trades at 26.4 times earnings.

Share price
₹1,200.00 (20 Nov 2026)
Market cap
₹1,19,700 Cr (20 Nov 2026)
P/E
26.42 (20 Nov 2026)
Revenue
₹7,910 Cr (September 2026 quarter)
Net profit
₹928 Cr (September 2026 quarter)
ROCE
21.1% (FY26)
ROE
21.2% (FY26)
Book value
₹279 (FY26)
Dividend yield
0.08% (last 12 months to 20 Nov 2026)
52-week high / low
₹1,266.60 / ₹835.50 (20 Nov 2026)
1-year return
29.3% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: ZYDUSLIFE

In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.